Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07829614 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

F182112 Phase Ib Clinical Study for the Treatment of Patients With Systemic Lupus Erythematosus

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The investigational drug is an injectable recombinant humanized anti-BCMA/CD3 bispecific antibody (code: F182112) that can simultaneously target the immune effector cell antigen CD3 and the antigen BCMA. Through a dual-targeting mechanism, it aims to guide the body's own immune system to target and kill B cells and plasma cells that overexpress BCMA.Based on the application of B cell depletion strategies in the treatment of autoimmune diseases, as well as the exploration of similar drugs in autoimmune diseases, we speculate that F182112 is also effective for autoimmune diseases. Therefore, we plan to carry out clinical research of F182112 in patients with systemic lupus erythematosus, with the aim of bringing more treatment options to patients.
Trial Details
NCT Number NCT07829614
Lead Sponsor Shandong New Time Pharmaceutical Co., LTD
Conditions
(from sponsor)		 Systemic Lupus Erythematosus (SLE)
Related terms Lupus Erythematosus, Systemic
Enrollment 64 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov